Abstract: The disclosure relates to compounds of Formula (I), as well as compositions, methods, uses, and kits comprising the same. The compounds, compositions, methods, uses, and kits provided herein are useful in treating diseases or disorders including cancer, HIV, and angiogenesis-related disorders.

Abstract: Biorenewable polyesters and polyester copolymers derived from camphoric acid, aromatic dicarboxylic acid and aliphatic diols and methods of making those copolyesters and articles comprising copolyesters are disclosed. The disclosed biorenewable copolyesters may can have a Mn of from about 5,000 Da to about 500,000 Da. Also disclosed are preparation methods of various monomers e.g., cis-1,4-anhydroerythritol and bis(2-hydroxyethyl) camphorate. The disclosed biorenewable polyesters and polyester copolymers can be used for production of various articles utilizing a conventional polyesters or polyester copolymers, to replace, in part or in whole, a conventional non-biorenewable polyesters or polyester copolymers.

Abstract: The invention is directed towards compounds, methods of stimulating myelination, stimulating proliferation of oligodendrocytes (OLs) or stimulating oligodendrocyte precursor cells and methods of treating diseases, disorders or symptoms thereof.

Abstract: Described herein are loupes shields. The shields can be easily attached to the loupes. The loupes shield is composed of a single filter that blocks harmful light. Additionally, the loupes shield includes a connector that permits the loupes shield to be attached to the loupes lens or housing that holds the loupes lens. The loupes shields described are useful in applications where it is desirable to protect the user from being exposed to damaging light. The loupes shields are useful in dental applications such as, for example, dental restorations, where light cure is required to cure the resin applied to a tooth during a dental restoration.

Abstract: Disclosed herein are compounds that selectively bind an expanded transcribed repeat r(G4C2)exp, prevent sequestration of RNA-binding proteins, and inhibit translation of repeat associated non-ATG (RAN) translation responsible for generation of toxic dipeptide repeats underlying diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The compounds and their pharmaceutical compositions are useful in treating a disease or condition characterized by an expanded G4C2 repeat RNA (r(G4C2)exp), such as ALS and FTD.

Abstract: Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting certain repeat-associated non-ATG (RAN) proteins in a subject (e.g., a subject having or suspected of having a disease associated with a CAG and/or CTG repeat expansion). In some embodiments, methods described by the disclosure comprise detecting one or more RAN proteins in a biological sample obtained from a subject by an immunoassay using one or more antibodies that target homopolymeric repeat regions of RAN proteins. In some embodiments, the disclosure relates to kits comprising one or more antibodies that target homopolymeric repeat regions of RAN proteins, and an immunoassay plate and/or reagents. In some embodiments, the disclosure provides methods of producing anti-RAN protein antibodies.

Abstract: In one aspect, the disclosure relates to methods for preparation of intermediates useful for the preparation of aryl-cycloheptene scaffolds. In a further aspect, the disclosed methods pertain to the preparation of compounds comprising an aryl-cycloheptene structure. The disclosed methods utilize abundant starting materials and simple reaction sequences that can be used to modularly and scalably assemble common such cores. In various aspects, the present disclosure pertains to compounds prepared using the disclosed methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: An aptamer-N-heterocyclic-carbene metal complex conjugate (aptamer-NHCM conjugate) or an aptamer-bis-N-heterocyclic-carbene metal complex conjugate (aptamer-bis-NHCM conjugate) includes an aptamer coupled through a hydrolytically stable bond to an N-heterocyclic-carbene metal complex (NHCM) or a bis-N-heterocyclic-carbene metal complex (bis-NHCM). The aptamer-NHCM conjugate is prepared where the chosen aptamer displays selective binding to a cell specific receptor, such that the cytotoxic NHCM can be directed specifically to cells responsible for a target disease (e.g., a specific cancer type). A method of preparing the aptamer-N-heterocyclic-carbene metal complex conjugate involves installing a coupling group to an N-heterocyclic-carbene metal complex that can specifically bond with a functional group on an aptamer; the bond, covalent or non-covalent, is stable hydrolytically in the absence of an environment that promotes intentional cleavage of the bond.

Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to TMJ implantation materials and implants (e.g., temporomandibular joint (TMJ) disc), methods of making TMJ implantation materials and implants, methods of forming a TMJ implantation material or an implant, and the like.

Abstract: Provided for herein are polynucleotides, including codon-optimized polynucleotides, encoding genes for use in, for example, virally-mediated gene therapy for Friedreich's ataxia. Some embodiments related to viral vector constructs for use in such gene therapy. Also provided are dosing regimens and therapeutic combinations or systems for use in modulating immune responses to such viral vectors.

Abstract: Autoregulatory systems that have been implemented to control the expression and activity of Cast 3d, including the activity of Cast 3d in vivo, thereby reducing collateral damage in cells at off-target sites (e.g., non-target messenger RNA transcripts. The autoregulatory system is in the form of a nucleic acid molecule comprising a zinc finger binding site, a promoter, and a nucleotide sequence encoding a Cast 3d fusion protein, and a transcriptional repressor domain, and wherein the Cast 3d fusion protein binds to the zinc finger binding site and represses transcription of the nucleotide sequence encoding the Cast 3d fusion protein.

Abstract: The present disclosure provides the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in treating a neurological disease associated with repeat expansions and/or RAN protein accumulation, reducing the level of one or more repeat associated non-ATG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and/or biological sample. Also provided is the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in inhibiting RAN protein translation in a subject and in a biological sample (e.g., cells, tissue). Also provided in the present disclosure are pharmaceutical compositions, Skits, and uses of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) for treating diseases associated with repeat expansions.

Abstract: The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.

Abstract: Provided herein are compositions and methods for packaging a recombinant adeno-associated vims (rAAV) particle comprising using inverted terminal repeats (ITRs) and rep genes of different serotypes and/or using chimeric rep genes.

Abstract: According to at least one aspect, a series of images of a scene are obtained, such as by a head mounted display. The scene includes a medical device and a tracking device, and the series of images including at least the tracking device. Relative pose information indicative of a relative spatial relationship between the tracking device and the medical device is accessed, the 3D representation of the patient is registered with the medical device using the series of images of the scene and the relative pose information, and a mixed reality visualization of the 3D representation of the patient and the medical device generating, based on results of the registering. The mixed reality visualization can further include a visual indication indicative of an alignment of the patient with the 3D representation.

Abstract: A system for secure testing and provisioning of an integrated circuit (IC) includes, in part, a secure reconfigurable key provisioning architecture (SLEEVE) module disposed in the IC, and a secure asset provisioning hardware entity (SAPHE) module. The IC may include, in part, a modified IEEE 1500 wrapper to control its operation modes. The SLEEVE module may include, in part, an encoding/decoding module and an unlocking module. The encoding/decoding module may include, in part, a decode key stream cipher module, an encode key stream cipher module, Seed Key programmable linear-feedback shift registers (LFSRs), Initialization Vector (IV) LFSRs, and configuration registers. The encoding/decoding module may be configured to generate key bits for decoding and encoding inputs and outputs of the IC. The unlocking module may include, in part, a pattern matching block and a counter. The unlocking module may be configured to enable write access to the configuration registers.

Abstract: Various embodiments of the present disclosure provide for accelerated segmentation for reverse engineering of integrated circuits. In one example, an embodiment provides for receiving an SEM image for an integrated circuit, performing filtering and binarization with respect to the SEM image, extracting information associated with filter sizes for the filtering, extracting signatures related to a distribution for background pixels and foreground pixels of the SEM image, extracting respective distance to mean signatures for the background pixels and the foreground pixels, and segmenting the SEM image based at least in part on the filter sizes and the respective distance to mean signatures to generate a segmented image for the integrated circuit.

Abstract: Provided herein are compositions comprising nicotine, or a salt thereof, and pilocarpine, or a salt thereof, useful for reducing the use of betel quid and/or achieving betel quid cessation (e.g., replacement therapy). Also provided herein are methods of using the compositions in reducing the risk of developing or reducing the progression of a disease (e.g., cancer, oral disease, neurological disease, or painful condition). Compositions of the present invention may be administered to a subject with an addiction, e.g., a betel quid addiction, areca nut addiction, and/or nicotine addiction.

Abstract: Apparatus, systems, and methods described herein relate generally to autonomous mobile units carrying a modular configurable battery system that may attach and power mobile units in transportation systems. A method can include determining charge levels, current positions, and transport speeds for an electric vehicle (EV), identifying one or more EVs in need of charging, and mobilizing a Mobile Charging Station (MoCS) to deliver one or more external batteries. A processor, with a memory including computer program code, can be configured to receive current charge level data for mobile battery-powered entities, identify one or more EVs to be charged and the proximity of both MoCS and physical battery stations, and send charging instructions to the EVs. A routing and charge transaction scheduling algorithm can be used to optimize the route of one or more battery-powered entities and to schedule charge transactions between the EV and MoCS and/or the battery station.

Abstract: Embodiments provide for predicting rowhammer attack vulnerability of one or more memory cells of a direct random access memory (DRAM) chip, the DRAM chip including a plurality of memory cells. An example method, determines, for each memory cell of a subset of memory cells of the plurality of memory cells, a leakage time t, a resistance of intrinsic leakage RL based at least in part on the leakage time t, an activation time of an adjacent aggressor row to flip a bit in the memory cell, a resistance of coupling leaking RSW based at least in part on the activation time, and a toggling count. The method identifies, based at least in part on one or more of the RSW, RL, or toggling count, whether the direct random memory access (DRAM) chip is vulnerable to a rowhammer attack.